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Understanding the cellular mechanisms of tumour growth is key for designing 
rational anti-cancer treatment. Here we used genetic lineage tracing to quantify 
cell behaviour during neoplastic transformation in a model of oesophageal 
carcinogenesis.  We found that cell behaviour was convergent across 
premalignant tumours, which contained a single proliferating cell population. 
The rate of cell division was not significantly different in the lesions and the 
surrounding epithelium. However, dividing tumour cells had a uniform, small 
bias in cell fate so that, on average, slightly more dividing than non-dividing 
daughter cells were generated at each round of cell division. In invasive cancers 
induced by KrasG12D expression, dividing cell fate became more strongly biased 
towards producing dividing over non-dividing cells in a subset of clones. These 
observations argue that agents that restore the balance of cell fate may prove 
effective in checking tumour growth, whereas those targeting proliferation may 
show little selectivity. 
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Introduction 
Epithelial tumours form when the cellular homeostasis of normal tissue is locally 
disrupted so that cell production exceeds cell loss (Fig. 1a).  This may result from the 
rate of tumour cell division being faster than that of normal cells.  A second 
possibility is that in tumours such as squamous cell carcinomas (SCC) that consist of 
a mixture of dividing and non-dividing cells, the proliferating tumour cells produce a 
higher proportion of dividing than non-dividing daughters1.  This bias in cell fate 
results in a progressive expansion in the proliferating cell population.  Thirdly, the 
rate of cell loss may be decreased within the tumour relative to the rate of cell 
production.  Here we set out to resolve which of these mechanisms contribute to 
squamous tumour growth in the oesophagus.  
 
Further insights into the pathogenesis of oesophageal SCC, currently the 6th 
commonest cause of cancer death worldwide, are urgently needed as even with the 
most aggressive treatment the majority of patients will die from their disease2, 3.  
Oesophageal SCC is strongly associated with tobacco exposure, and may be preceded 
by the development of non-invasive lesions called high-grade squamous dysplasias 
(HGD)4, 5. Oesophageal carcinogenesis has been successfully recapitulated in rodents, 
either by exposing animals to the mutagenic DNA alkylating agent diethylnitrosamine 
(DEN), which is found in tobacco smoke, or by replicating some of the genomic 
alterations found in human SCC in transgenic mice6-12.   
Despite the availability of mouse models, quantifying the behaviour of proliferating 
cells within intact tumours remains challenging. One potential approach is lineage 
tracing, in which expression of a heritable genetic label is induced in individual 
proliferating cells (Supplementary Fig. 1a-c)13, 14.  As the progeny of the labelled 
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cell proliferate and differentiate, they generate clusters of labelled cells, termed 
clones, as they derive from a single cell. Analysis and statistical modelling of the 
number of cells in cohorts of simultaneously labelled clones sampled over a 
prolonged time course has revealed normal cell behaviour and how it is altered by 
specific oncogenic driver mutations in several tissues, including the oesophageal 
epithelium15, 16.  However, the application of this approach to tumours has hitherto 
been frustrated by extensive inter- and intra-tumoural heterogeneity, which renders 
the inference of cell behaviour infeasible14.  
 
Resolving tumour cell behaviour requires a protocol that generates highly similar 
lesions at a defined time point.  Murine oesophageal epithelium is an ideal tissue in 
which to address this challenge.  The normal tissue consists of layers of keratinocytes 
with proliferation confined to the basal layer13.  Lineage tracing has shown that the 
oesophageal epithelium contains only one type of proliferating cell, termed a 
progenitor. The outcome of individual progenitor divisions is unpredictable, 
generating either two progenitors or two non-dividing, differentiating cells or one cell 
of each type (Fig. 1b).  In homeostasis, the probabilities of each division outcome are 
balanced so that an equal number of progenitors and non-dividing cells are generated 
across the progenitor population. Wounding, however, drives the progenitors local to 
the injury to transiently produce an excess of proliferating daughters until the 
epithelium is repaired13, 17.  Mutations inactivating the Notch pathway also bias fate 
towards proliferation, suggesting the plasticity in progenitor cell behaviour that 
enables wound healing is a potential vulnerability during neoplastic transformation15, 
18.    
 
 5 
Chemical carcinogens such as DEN induce oesophageal tumours but the number of 
lesions and the time they take to develop varies widely between animals6. We drew on 
the widely used and well-characterised two-stage carcinogenesis protocol in the skin, 
speculating that following mutagen treatment with a tumour promoting agent might 
drive the formation of a cohort of tumours sharing a similar phenotype19.  We noted 
that side effects of the multikinase inhibitor Sorafenib include induction of SCC of the 
skin and head and neck in patients treated for liver, kidney and thyroid cancers20-22.  
This motivated us to test whether Sorafenib could promote oesophageal tumour 
formation in DEN treated mice. 
Here we report that the combination of DEN followed by Sorafenib was effective at 
inducing cohorts of tumours that are sufficiently similar to permit the quantification 
of cell dynamics using transgenic cell proliferation and lineage tracing assays.  We 
resolved cell behaviour in promoter treated epithelium, HGD and SCC. The data 
argues that tumours contain a single proliferating cell population whose behaviour is 
only subtly perturbed from that of normal progenitors. 
 
Results 
Sorafenib promotes the formation of high grade dysplasias 
We set out to determine if Sorafenib could promote squamous carcinogenesis in the 
oesophagus, beginning by investigating the effect of treatment with Sorafenib alone. 
10 days of dosing induced a marked dose-dependent increase in proliferation marker 
expression (Fig. 1c,d, Supplementary Fig. 2a-c).  Treatment for 28 days at a 
50mg/Kg dose resulted in decreased phosphorylation of ERK and AKT (Fig. 1e-g, 
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Supplementary Fig. 2d-f).  However, tissue integrity was preserved and no tumours 
developed (Supplementary Fig. 2g, Supplementary Table 1), even when the 
duration of treatment was extended to 56 days. Apoptosis was negligible 
(Supplementary Fig. 2h). Hence, Sorafenib on its own, increased proliferation but 
was not tumourigenic. 
Next we studied the combination of Sorafenib and the mutagen DEN. Mice were 
administered Sorafenib or vehicle control for 28 days after 56 days of exposure to 
DEN (Fig. 2a). The combination of DEN and Sorafenib generated an average of 3 
macroscopic tumours per animal with histological features of HGD (loss of normal 
differentiation, nuclear atypia and loss of cell polarity extending through the entire 
thickness of the epithelium) (Fig. 2b-e, Supplementary Table 1)4. In contrast, 
animals treated with DEN and vehicle developed small areas of focal hyperplastic 
epithelium at a frequency of less than one lesion per mouse (Fig. 2d,e, 
Supplementary Table 1).  
We next characterised the DEN/Sorafenib induced HGD further.  Consistent with the 
disruption of terminal differentiation seen histologically, we observed a loss of 
expression of the cornified envelope precursor proteins LOR and FLG in lesions by 
immunostaining (Fig. 2f, Supplementary Fig. 3a).  Expression of KRT14, confined 
to the basal layer in normal epithelium, was widespread, and KRT4, normally 
detected in the first suprabasal layer was only seen in and above the 3rd and 4th 
suprabasal cell layers (Fig. 2f). We also observed increased expression of the 
keratinocyte stress induced proteins KRT6, induced in squamous tumours in humans 
and mice and KRT17, a regulator of tumour associated transcription (Fig. 2g, 
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Supplementary Fig. 3b)23-25. We detected apoptosis in only 0.08 +/- 0.05% (mean+/- 
s.e.m.) of cells (Supplementary Fig. 2h).    
The dysplastic cells did not breach the basement membrane but protruded into the 
underlying submucosa (Fig. 2h). 3D confocal imaging revealed substantial stromal 
remodelling beneath the lesions.  There was marked angiogenesis and 
lymphangiogenesis with a leukocytic infiltrate including CD11b and CD3 positive 
cells closely associated with the deep margin of HGD, features also seen in murine 
and human squamous dysplasia and SCC (Fig. 2i-k, Supplementary Fig. 3c)26-30.  
We concluded that Sorafenib promotes tumour formation in DEN treated epithelium. 
We next investigated whether the common histological phenotype of the lesions was 
reflected at a transcriptional level. Whereas the transcriptomes of HGDs and normal 
adjacent epithelium differed markedly, there was comparatively little variation 
between HGDs (Fig. 3a). Gene ontology categories that were significantly different 
between normal epithelium and HGD included keratinocyte differentiation and 
inflammation associated transcripts, consistent with our findings above 
(Supplementary Tables 2, 3). Transcripts of genes involved in RNA splicing, a 
process dysregulated in epidermal carcinogenesis, were also differentially expressed 
(Fig. 3b)31. We validated the relative expression of selected mRNAs in epithelium 
and HGDs by quantitative RT-PCR, observing marked upregulation of cytoskeletal 
associated transcripts (Fig. 3c). 
Clonal origin of HGD lesions 
Malignant transformation is thought to be a process in which lesions originate from 
the progeny of a single cell that progressively acquires multiple oncogenic genomic 
alterations32, 33. However, dysplastic lesions in several mouse and human tissues have 
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been shown to be polyclonal34-39.  We therefore investigated the clonal origin of the 
HGD lesions by genetic lineage tracing.  We induced a heritable genetic marking with 
the confetti allele, which labels cells with one of four different fluorescent proteins 
(Supplementary Fig. 1a,b) 40.  Reporter expression was induced in individual basal 
cells by transient expression of cre recombinase-mutant oestrogen receptor fusion 
protein (creERT) from a xenobiotic inducible Cyp1a1 (Ah) promoter following 
injection of low dose β-napthoflavone and tamoxifen in AhcreERTRosa26flConfetti/wt 
mice41.  Animals were then treated with DEN and Sorafenib and epithelial 
wholemounts of HGD lesions imaged (Fig. 3d).  If lesions arose from the clonal 
progeny of a single cell, they would be either unlabelled or completely labelled with a 
single colour. If, however, HGD derived from multiple cells, variegated labelling with 
multiple different coloured clones would be seen.  We observed a mean of 2.7 clones 
(range 1-6) in 9 labelled lesions, which ranged widely in size (n=5 animals) (Fig. 3e-
g). Similar results were obtained when the experiment was repeated with a single 
colour labelling system in AhcreERTRosa26flYFP/wt mice, in which cells are labelled 
with a yellow fluorescent protein (YFP) reporter (Supplementary Fig. 1c, 
Supplementary Fig. 3d-g)13.  We conclude that HGD have multiple cells of origin. 
KrasG12D expression in combination with DEN/Sorafenib treatment results in 
invasive squamous cell carcinomas 
We speculated that altering the protocol might generate invasive SCC rather than 
HGD. We noted that mutations, amplifications or overexpression of growth factor 
receptor tyrosine kinases and genes in their downstream signalling pathways, 
including KRAS, are present in the majority of human oesophageal SCCs42-44.  
Furthermore, oncogenic KRAS mutations are frequent in cutaneous SCCs in patients 
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treated with Sorafenib45.  These observations led us to investigate the effects of 
inducing the oncogenic KrasG12D mutant in oesophageal epithelium after DEN 
exposure and prior to treatment with Sorafenib (Supplementary Fig. 1d)46.  This 
protocol resulted in lethal, invasive SCCs in 11/14 animals (Fig. 4a-d, 
Supplementary Table 1).  We observed increased phospho-Erk levels in the 
carcinomas, consistent with Kras activation in the lesions (Fig. 4e).  Consistent with 
our findings in dysplasias, KRT14 stained positive throughout the tumours, while 
expression of terminal differentiation marker LOR was abrogated (Supplementary 
Fig. 4a,b).  The carcinomas shared a similar transcriptome (Fig. 4f). Among the 
differences in transcription between HGD and SCC were significant induction of the 
inflammation associated mRNAs Ifngr2 and Fcer1g and changes consistent with Kras 
activation in SCC (Fig. 4g,h, Supplementary Fig. 4c). A limitation of inducing SCC 
with this protocol is that we were unable to use lineage tracing to determine whether 
the tumours were monoclonal or polyclonal in origin. 
Proliferating cell dynamics in Sorafenib treated epithelium 
The data above show that the combination of DEN and Sorafenib was effective in 
inducing HGD and SCC that shared similar features.  We therefore set out to quantify 
how proliferating cell behaviour changed in promoter treated epithelium, HGD and 
SCC.   
We began by analysing the effect of Sorafenib treatment by using the dilution of a 
transiently expressed transgenic histone-green fluorescent protein (HGFP) to infer the 
mean rate of epithelial cell division13, 47, 48.  Transgenic animals were treated with 
doxycycline (dox) to induce HGFP transcription from a synthetic dox-regulated 
promoter, resulting in high level expression of HGFP throughout the epithelium 
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(Supplementary Fig. 1e)49, 50.  Following withdrawal of dox, HGFP levels were 
measured by confocal imaging of epithelial wholemounts.  Histone mRNA is short 
lived, so HGFP message is unlikely to persist following dox withdrawal and the 
cessation of transcription51, 52.  Assuming that the rate of HGFP protein degradation is 
small compared with the cell cycle time, the rate of HGFP decrease will reflect the 
rate at which it is diluted by cell division (Fig. 5a-c, Supplementary Table 4). 
Analysis of HGFP levels indicated the mean cell division rate rose from once every 
3.5 days in controls to a rate of once a day during Sorafenib treatment 
(Supplementary Fig. 5a,b, Supplementary Note 2.1) .   
To address how the fate of individual progenitor cells was perturbed by treatment 
with Sorafenib, we used lineage tracing, inducing sparse genetic labelling with YFP 
to yield well-separated clones in AhcreERTRosa26flYFP/wt mice during a course of 
Sorafenib treatment (Fig. 5d)13.  12 days after clonal induction, animals were 
sacrificed, and multicellular YFP expressing clones (233 from 3 animals) imaged 
(Fig. 5d-f, Supplementary Fig. 5c-f, Supplementary Table 4). To assess whether 
the clone size data could be accommodated within the cell fate paradigm of normal 
OE (Fig. 5g), we implemented cell fate rules in a stochastic model, which was 
simulated for a wide range of parameters (Supplementary Note 1.2.2). Taking the 
cell cycle times determined by HGFP dilution as a prior, we found the best match of 
model and data using Bayesian inference (Fig. 5f). This confirmed that the data 
complies with the same paradigm as normal epithelium, but with a marked increase in 
both the proportion of divisions leading to asymmetric fate and the rate of cell 
stratification, in line with the increased cell division rate (Fig. 5f,g, Supplementary 
Table 5, Supplementary Note 2.2).  We subsequently repeated the experiment 
analysing clones in Sorafenib treated epithelium 21 days after induction.  The 
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observed clone size distribution at 21 days accurately matched the predicted clone 
size distribution based on the parameter estimates from the 12 day experiment, 
confirming our cell fate model (Supplementary Fig. 5g-j, Supplementary Table 4). 
We further tested the predictions of the lineage tracing analysis by independent 
assays, which were consistent with model predications (Methods, Supplementary 
Fig. 5k-q, Supplementary Note 2.2).  We concluded that Sorafenib established a 
new ‘steady-state’ with a faster rate of cell turnover than control tissue, sustained by 
the same single dividing cell population that maintains the normal epithelium. 
Cell dynamics in dysplasia 
Next we investigated proliferating cell behaviour within HGD lesions. To map the 
location of proliferating cells, animals were injected with EdU (Fig. 6a)53. After 24 
hours, the vast majority of EdU+ cells were found at the edge of lesions (Fig. 6b). 
However, 5 days later, residual EdU+ cells were found in the centre of the lesion, 
arguing non-dividing cells migrate from the proliferative rim to the core of the lesion 
where they accumulate (Fig. 6c).  This was confirmed by HGFP dilution assay, which 
showed that cells retaining detectable levels of HGFP remained in the centre of the 
lesions for at least 38 days after dox withdrawal, but were absent elsewhere in the 
tissue (Fig. 6d,e).  We concluded that HGD were characterised by a centripetal 
migration of cells from the proliferative margin to the non-dividing centre, a 
phenomenon also reported in human squamous tumours1. A possible explanation for 
the retention of non-dividing cells is that the disrupted expression of proteins required 
for late terminal differentiation reduces the rate of shedding of dysplastic cells from 
the surface of the lesion in comparison with normally differentiated cells in the 
adjacent epithelium (Fig. 2f, Supplementary Fig. 3a). 
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Next we estimated the rate of cell division in HGD and the adjacent epithelium (Fig. 
6f-i, Supplementary Fig. 6a-d, Supplementary Table 4). Analysis of HGFP 
dilution showed the mean cell division rate was once per day both in the lesion and 
the surrounding epithelium, assuming the stability of HGFP is not altered by 
neoplastic transformation (Fig. 6h,i, Supplementary Fig. 6d, Supplementary Table 
5, Supplementary Note 2.1). To track the fate of individual cells in HGD, we 
performed lineage tracing in YFP reporter mice, imaging clones within wholemounts 
at 13 and 22 days post-induction (Fig. 7a-c, Supplementary Fig. 6e,f, 
Supplementary Table 4). The clone size distribution remained unimodal, consistent 
with dividing cells belonging to a single progenitor population following a defined 
stochastic fate. We therefore sought the simplest modification of normal cell 
dynamics that could accommodate the observed clone sizes, in the form of a constant 
statistical bias in cell fate towards the production of proliferating cells. We thus 
simulated the original model relaxing the previous restriction on equal cell fate ratios, 
and tested this model on the clone size distributions through Bayesian inference (Fig. 
1b, Supplementary Note 2.3). This showed an excellent agreement between 
experiment and theory and gave a bias of around 4% towards divisions producing two 
cycling over two non-dividing cells (Fig. 7c,d, Supplementary Table 5, 
Supplementary Note 2.3). The rate of cell loss was also reduced (Fig. 7d, 
Supplementary Table 5, Supplementary Note 2.3).  This is consistent with both the 
observed disruption of the differentiation process that occurs prior to cell shedding 
from the epithelial surface and the accumulation of non-dividing cells in the lesion 
core (Fig. 2f, Supplementary Fig. 3a, Fig. 6c,e).  Analysis of the clone size 
distribution in the surrounding epithelium indicated the cell dynamics were not 
significantly different from those of epithelium in mice treated with Sorafenib alone, 
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suggesting that the effects of the combination of DEN and Sorafenib treatment on cell 
behaviour are confined to the HGD lesions (Supplementary Fig. 6g).  To further 
validate the analysis, we repeated the experiment in mice carrying the confetti 
reporter allele, which allows labelling with four different colours, thereby reducing 
the probability that clones with the same colour merge to create a misleadingly large 
apparent ‘clone’ (Fig. 7e-g, Supplementary Note 2.3). We obtained similar results to 
YFP for all parameters but the loss rate, which was increased in the confetti 
experiment. This discrepancy may be attributed to the higher sensitivity of detection 
of labelled cells in the single colour assay, in which immunostaining was used to 
visualise YFP expression (see Methods). We concluded that a single proliferating cell 
population with a small constant cell fate bias towards the production of dividing cells 
is responsible for the growth of the dysplastic lesions (Fig. 7d).  
This analysis made the counterintuitive prediction that the proportion of dividing cells 
amongst the total cell population should be decreased within HGD compared with the 
surrounding epithelium, as the decreased rate of cell loss in HGD would result in the 
accumulation of non-dividing cells.  The proportion of cells expressing the 
proliferation associated antigen Ki67 was indeed reduced within HGD (Fig. 7h).  
Cell dynamics in squamous cell carcinoma 
Finally, we investigated proliferating cell behaviour in SCC.  We performed lineage 
tracing in triply transgenic AhcreERTRosa26flYFP/wtKrasflG12D/wt animals, induced after 
DEN exposure and prior to Sorafenib treatment (Fig. 8a-h, Supplementary Fig. 7a-
d, Supplementary Table 4).  The YFP allele was less efficiently recombined than the 
KrasG12D allele, resulting in sparse labelling in tumours.  In these experiments, the 
clones reflect the fate of labelled cells and their progeny from when they were 
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labelled in normal appearing epithelium at the end of DEN treatment until they are 
sampled within SCC.  We observed that 26/31 SCC contained an average of 5 (range 
1-20) YFP positive clones (Fig. 8e). Two thirds of the clones had a size distribution 
quantitatively consistent with the cell dynamics seen in HGD (Fig. 8b,f,g, 
Supplementary Fig. 7c, Supplementary Note 2.4). The sizes of the vast majority of 
the remaining clones could be captured within the same model paradigm, but with a 
larger bias towards proliferating cell fate (Fig. 8c,h, Supplementary Fig. 7d, 
Supplementary Note 2.4). Only 2% of clones expanded significantly faster than the 
model prediction (Fig. 8d,f), suggesting that the same paradigm of progenitor 
dynamics applies to almost all clones in SCC, but with a variable bias in cell fate 
(Fig. 8i).  Strikingly, as with HGD, the proportion of Ki67 positive cells was lower in 
SCC than in the surrounding normal epithelium (Fig. 8j, Supplementary Fig. 7e). 
Conclusion 
In summary, the DEN/Sorafenib carcinogenesis protocol generates multiple, 
synchronous and phenotypically similar oesophageal HGDs.  Additional expression 
of an oncogenic Ras allele generates invasive SCC.  These tumours are sufficiently 
similar to allow the quantitative resolution of cell dynamics and offer a model of 
carcinogenesis that can be combined with transgenic tools to explore many other 
aspects of tumour biology. 
Linage tracing reveals that cells in dysplasias share a common dynamics despite their 
polyclonal origin. It remains to be resolved whether a single clone recruits 
surrounding cells or whether multiple clones collaborate in establishing a lesion. 
Within oesophageal tumours, we show that dividing cells are a single population with 
a bias towards the production of dividing over non dividing daughter cells and no 
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significant change in the rate of cell division (Supplementary Fig. 7f).  In dysplasia 
cell behaviour is remarkably uniform with a small constant fate bias.  In contrast, 
early carcinoma is characterised by the emergence of a sub-set of clones with an 
increased bias towards proliferation that compete for dominance within the tumour33, 
54. 
Our results also argue that the ‘cancer stem cell’ hypothesis, which proposes that 
tumour expansion depends on a hierarchy of proliferating cells, does not apply to 
squamous neoplasia in mice55, 56.  We conclude that targeting imbalanced cell fate 
may provide an attractive strategy to arrest tumour progression.  
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Figure Legends 
 
Figure 1 Cell dynamics in oesophageal squamous carcinogenesis. (a) Normal 
oesophageal epithelium is maintained by a single population of progenitor cells that 
divide to generate dividing (pink) and post mitotic cells (white), which exit the basal 
layer. In homeostatic epithelium cell production (green arrow) balances cell loss (red 
arrow) as proliferating cells generate equal proportions of dividing and non-dividing 
cells on average. In tumours, an excess of cells is generated locally through one or 
more of: faster cell division, indicated by the clock, an imbalance in cell fate with a 
bias towards producing proliferating over non-dividing progeny, Δ, or a decrease in 
the rate of cell loss relative to the rate of cell production. (b) The outcome of 
individual progenitor divisions is unpredictable, generating two dividing progenitors 
or two non-dividing, differentiating cells in symmetric divisions or one cell of each 
type with the probabilities shown; r is the probability of a symmetric division 
outcome. In homeostasis, on average equal proportions of dividing and non-dividing 
cells are generated. During wound healing, local progenitor cells transiently generate 
an excess of dividing cells until the epithelium is repaired. The probability of 
generating two dividing cells is increased by Δ, a measure of cell fate bias towards 
producing proliferating over non-dividing progeny.  (c,d) Proliferation in Sorafenib 
treated oesophageal epithelium. (c) Protocol. Animals were given Sorafenib or 
vehicle only (Control) for 10 days and injected with EdU (purple arrow) 1 hour before 
being culled. (d) Confocal z stacks showing ‘top down’ views of typical epithelial 
wholemounts, representative of 3 animals per group; stained for Ki67 (green), EdU 
(magenta), 40,6-diamidino-2-phenylindole (DAPI, blue). Scale bar, 50 µm.  (e-g) 
Effect of Sorafenib on ERK phosphorylation.  (e) Protocol. (f) Representative 
confocal images of epithelial cryosections stained for P-ERK (Thr202/Tyr204, green), 
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basal marker ITGA6 (white) and DAPI (blue). Scale bar, 50 µm. Arrow, cells positive 
for P-ERK. Image is representative of sections from 3 animals/group. (g) Mean 
percentage of basal cells staining positive for P-ERK, (* p=0.026 by t test, n=3 
animals/group). See Supplementary Table 4 for source data for g. 
 
Figure 2: Characterisation of dysplastic lesions 
(a) Protocol. Animals were treated with DEN for 8 weeks followed by vehicle control 
or Sorafenib for 4 weeks. (b) Representative epithelial wholemount with lesions 
(arrows) following DEN and Sorafenib treatment. Scale bar, 1 mm. (c) Haematoxylin 
& eosin stained section of a typical high grade dysplastic lesion, arrow indicates 
parakeratosis. Scale bar, 100 µm. Image representative of 8 lesions. (d,e) Number of 
lesions per animal (d) and lesion area (e) in DEN and vehicle (DEN+V) and DEN and 
Sorafenib (DEN+S) treated animals. **p=0.003 by t-test, n=12 per group. 
***p=0.0001 by Mann-Whitney test, n=28 lesions for DEN+S and 15 lesions for 
DEN+V group. (f) Differentiation within lesions. Confocal image of cyrosection from 
lesion stained for a terminal differentiation marker, the cornified envelope precursor 
protein LOR (green), KRT4 (magenta) and basal cell marker KRT14 (white). Scale 
bar, 200 µm. (g) Expression of keratinocyte stress induced protein KRT6. Confocal 
image of cryosection stained for KRT6 (green) and basal cell marker ITGA6 (white). 
Scale bar, 200 µm. Images f,g are typical examples of 3 lesions.  (h-k) Stromal 
changes beneath HGD lesions. (h) Brightfield image of submucosa paired with 
wholemount shown in b. Arrows indicate lesions. Scale bar, 1 mm. Image 
representative of 8 wholemounts. (i-k) Projected confocal z stacks of stroma 
underlying lesions (arrowed) stained for i, capillary endothelial marker CD31 (green), 
lymphatic endothelial vessel marker LYVE-1 (magenta) and KRT14 (white); scale 
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bar, 200 µm. (j,k) Immune infiltrate in stromal wholemount stained for myeloid 
marker CD11b (green) and KRT14 (magenta) (j) and lymphoid marker CD3 (green) 
and KRT14 (magenta) (k). Scale bar, 100 µm.  Each image is representative of at least 
3 tumours.  See Supplementary Table 4 for source data for d and e. 
  
Figure 3: Transcription and origin of dysplasias 
(a) Hierarchical clustering of normalised expression values using complete linkage of 
transcripts from tumours and adjacent normal appearing epithelium. Heat map 
indicates Z scores.  Arrow indicates sample of apparently normal epithelium 
intermediate between normal and tumour groups. (b) Interaction map of proteins 
implicated in RNA splicing encoded by transcripts downregulated in tumours. (c) 
Quantitative PCR with reverse transcription of selected transcripts in HGD compared 
with adjacent control epithelium, relative to Hprt messenger RNA. Krt6b, Krt17 and 
Sprr2f represent differentiation-associated transcripts, Ccnd2 proliferation-associated 
and Fcer1g inflammation-associated mRNAs; Raf1 is implicated in oncogenic 
signalling pathway. Values are means of n=9 independent biological replicates, 
normalised to control (=1). Error bars are s.e.m. *P<0.05 **P<0.01; ***P<0.001 by 
Mann Whitney test.  (d-g) Origin of HGD lesions. (d) Protocol. Single cell labelling 
was induced in AhcreERTRosa26flConfetti/wt mice and animals subsequently treated with 
DEN and Sorafenib to induce lesions. Possible outcomes are shown. Clonal lesions, 
derived from a single cell would be either unlabelled or completely labelled with a 
single colour, while the presence of multiple coloured and/or unlabelled areas would 
indicate multiple cells of origin.  (e) Oblique view of 3D rendered confocal Z stack of 
typical lesion, dotted white line indicates lesion edge, GFP green, YFP yellow, RFP 
red, and Itga6 white. Scale bar, 200 µm. Image representative of 9 lesions. (f) Clones 
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per lesion (n=9 lesions from 5 animals). Line indicates mean. (g) Clone area (n=13 
clones, from 3 lesions in 3 animals). Line indicates mean.  See Supplementary Table 
4 for source data for c, f and g. 
 
Figure 4: Expression of mutant KrasG12D induces SCC.  
(a) Protocol. AhcreERTRosa26wt/flYFPKraswt/G12D transgenic mice were administered 
DEN prior to induction of the KrasG12D mutant, followed by Sorafenib treatment for 
42 or 56 days. (b) Haematoxylin & eosin staining of representative section of typical 
SCC, image typical of 26 tumours. Scale bar, 250 µm. (c) Close up of area of invasion 
in b. Scale bar, 50 µm, T, tumour, M, muscle. (d) Survival of induced 
AhcreERTRosa26wt/flYFPKraswt/G12D (KrasG12D) and AhcreERTRosa26wt/flYFPKraswt/wt 
(WT) animals (P=0.0001 by Log Rank test, n=11 per group). Arrows indicate time 
points of sampling for clonal analysis (see Fig. 8). (e) Typical cryosection of SCC in 
induced KrasG12D animal treated with Sorafenib, stained for Phospho-ERK (P-ERK, 
red) and ITGA6 (white). Scale bar, 200 µm, 100 µm, inset.  (f) Gene expression array 
analysis was performed on 12 SCCs from 4 AhcreERTRosa26flYFP/wtKrasflG12D/wt 
animals, induced after DEN exposure and prior to Sorafenib treatment. Hierarchical 
clustering of normalised expression values using complete linkage of transcripts from 
SCCs. Heat map indicates Z scores. (g,h) Quantitative PCR with reverse transcription 
of selected transcripts in SCC compared with control epithelium (g) or HGD (h). 
Transcript levels normalised relative to Hprt messenger RNA. Krt6b, Krt17 and 
Sprr2f are differentiation-associated, Ccnd2 and Ctnnb1 proliferation-associated and 
Myd88, Fcer1g and Ifngr2 inflammation-associated transcripts. Raf1, Pten and Igfbp2 
are implicated in oncogenic signalling. Values are means of n≥4 independent 
biological replicates, normalised to control (=1). Error bars are s.e.m. *P<0.05 
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**P<0.01; ***P<0.001 by Mann Whitney test.  See Supplementary Table 4 for 
source data and exact P values for d, g and h. 
 
Figure 5 Sorafenib accelerates tissue turnover. (a) Protocol. Transgenic 
R26M2rtTA/TetO-HGFP mice were treated with Sorafenib and doxycycline (dox) to 
induce expression of a Histone2BJ-GFP fusion protein (HGFP). After withdrawal of 
dox, HGFP is diluted by cell division. HGFP levels were quantified at the time points 
shown. (b) Confocal images show ‘top down’ views of representative unstained 
epithelial wholemounts at indicated times. Scale bar, 20 µm. (c) HGFP dilution. Box 
plots of HGFP fluorescence intensity in at least 300 cells per animal (n=3 animals per 
time point, 4 animals at 72h) following Dox withdrawal. Box indicates 25th and 75th 
percentiles, centre line is median, whiskers indicate range. (d-f) Lineage tracing in 
Sorafenib treated AhcreERTRosa26-/flYFP transgenic mice. (d) Protocol. Clonal density 
labelling was induced (green arrow) after 28 days of Sorafenib treatment, which 
continued for a further 12 days. Animals were injected with EdU (purple arrow) 
1 hour before being culled. (e) Rendered confocal z stacks of wholemounts showing 
representative lateral views of clones; green is YFP and white is basement membrane 
marker ITGA6. Scale bar, 20 µm. Image is typical example of 233 clones. (f) Clone 
size distribution (frequency of clones containing a given number of cells) in 
Sorafenib-treated animals, 12 days post labelling. Points are experimental data (n=233 
clones from 3 animals), lines model predictions for the best fit parameters and the 
blue area error margins (standard deviation), see Supplementary Note 1 and 2.2. 
(g) Progenitor cell behaviour inferred from clone size distributions in Sorafenib and 
control treated animals, showing a marked increase in the cell division and 
stratification rates and in the proportion of divisions leading to asymmetric fates, i.e. 
 25 
generating one dividing and one non-dividing cell. See Supplementary Table 4 for 
source data for c and f and Supplementary Table 5 for fitting error margins in g.    
 
 
Figure 6 Proliferation, migration and cell retention in HGD lesions. (a-c) EdU 
lineage tracing. (a) Protocol. Lesions were induced and animals injected with EdU 
(purple arrow) 1 or 5 days before culling. (b,c) ‘Landscape’ views of rendered 
confocal Z stacks of wholemounts 1 day (b) or 5 days (c) after labelling; white dashed 
line indicates lesion margin, EdU (red), basal marker ITGA6 (white). Scale bar, 100 
µm. Images are typical of 3 tumours per time point. (d,e) Label retention in HGD 
lesions. (d) Protocol. Lesions were generated in R26M2rtTA/TetO-HGFP animals, 
followed by dox to induce HGFP expression. After dox withdrawal, HGFP diluted for 
38 days. (e) Rendered confocal z stacks showing ‘landscape’ view of wholemount. 
Dashed white line is lesion margin. HGFP (green) and ITGA6 (white). Scale bar, 
50 µm. Image is representative of 3 lesions. (f-i) Measuring the cell division rate in 
HGD and adjacent epithelium. (f) Protocol. Lesions were generated in 
R26M2rtTA/TetO-HGFP mice. dox was then given for 4 weeks, withdrawn and samples 
collected over 72 hours. (g) Confocal image, representative of 6 lesions, from edge of 
dysplasia showing HGFP fluorescence (green), basal marker ITGA6 (white) and 
tumour associated cytokeratin KRT6 (magenta). Scale bars, 50 µm and 20 µm, 
respectively. Arrows indicate the border of dysplasia (HGD) and adjacent epithelium 
(A). (h) Ratio of HGFP intensities in adjacent epithelium (A) to HGD after 72 hours 
(n=6 lesions). (i) Mean cell generations (number of completed cell divisions since 24 
hours post dox withdrawal) in HGD (black; n=4 animals (24h and 48h); 6 animals at 
72h) and adjacent epithelium (purple; n=3 animals per time point) (see Methods, 
Supplementary Note 2.1, Supplementary Fig. 6b,c). Error bars are of the 
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logarithmic HGFP fluorescence levels, due to mouse-to-mouse variation (see 
discussion in Supplementary Note 2.1). The dashed line represents a slope of 1/day. A 
least-squares linear regression yields a slope of 0.99 ± 0.01 (s.e.m.)/day in HGD and 
0.97 ± 0.06 in adjacent epithelium, which estimates the cell division rate (see 
Supplementary Note 2.1).  See Supplementary Table 4 for source data for h and i. 
 
Figure 7: Cell dynamics in HGD lesions. (a-d) Lineage tracing in dysplastic lesions. 
(a) Protocol. After generating dysplasias in AhcreERTRosa26-/flYFP mice, YFP was 
induced at clonal density and samples imaged 13 days later. (b) Rendered confocal z 
stacks showing typical ‘landscape’ view, representative of 19 lesions, containing 
YFP+ clones (green, magenta is EdU and white is ITGA6). Scale bar, 100 µm. (c) 
Clone size distributions 13 days after induction. Points are experimental data (n=100 
clones), lines model fits and blue area indicates standard deviation. Note that sizes > 
40 may be attributed to clone fusions (see Supplementary Note 2.3). (d) Model: 
dynamics of proliferating cells (pink) in dysplasias, adjacent epithelium is shaded 
purple, see Supplementary Table 5 for error margins.  (e-g) Cell dynamics in HGD 
in AhcreERTRosa26flConfetti/wt mice. (e) Protocol. Dysplasias were generated prior to 
induction of the confetti reporter at clonal density. Samples were imaged 10 days or 
21 days later. (f) Rendered confocal z stacks showing ‘landscape’ view of a 
representative example of 21 lesions containing one or more confetti clones (yellow is 
YFP, red RFP, magenta is DAPI). Scale bar, 100 µm. (g) Clone size distribution 10 
days after induction. Points are experimental data (100 clones from 3 animals), line 
model fit and blue area indicates standard deviation (see Supplementary Note 2.3). 
(h) Mean Ki67+ cells as a percentage of total nucleated cells in HGD and adjacent 
epithelium (A) (**p<0.0072 by t-test, n = 5 tumours, from 4 mice). See 
Supplementary Table 4 for source data for c, g and h.   
 27 
 
 
Figure 8: Cell dynamics in Ras-driven SCCs. 
 (a) Protocol. AhcreERTRosa26wt/flYFPKraswt/G12D transgenic mice were administered 
DEN prior to simultaneous induction of the KrasG12D mutant and YFP, followed by 
Sorafenib treatment for 42 or 56 days. (b-d) Examples of clones. Reconstructed 3D 
rendered confocal z stacks of representative clones in vibratome sections of SCCs 
stained for YFP (green) and ITGA6 (white). Scale bar, 100 µm. Images typical of 147 
clones. (e) Clones per tumour (n=31 tumours, from 16 animals). Line indicates mean. 
(f) Clone sizes at 42 and 56 days after induction. (g, h) Clone size distributions 42 
days after induction. Points are experimental data, lines model predictions and blue 
area indicates standard deviation. Data are binned in intervals of 10 cells per clone (g) 
and 100 cells per clone (h), respectively. (g) Clones < 150 cells (n=65 clones) 
overlying predictions of dysplasia model (Fig. 7d). (h) Clones > 150 cells (n=33 
clones), with theoretical prediction (exponential function, see Supplementary Note 
2.4). Clone size is rescaled (size relative to mean clone size). (i) Proliferating cell fate 
in oesophageal squamous cell carcinoma. Δ indicates cell fate bias towards producing 
proliferating progeny, low in smaller SCC clones (blue), higher in larger SCC clones 
(green). (j) Mean percentage Ki67+ cells/total nucleated cells in SCC and adjacent 
epithelium (A), (*p=0.022 by t-test, n=4 tumours). See Supplementary Table 4 for 
source data for f-h and j.  
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Supplementary Note
In this supplementary note we outline the mathematical analysis of the data and the mod-
elling scheme for cell fate dynamics in oesophageal epithelium treated with diethylnitrosamine
(DEN) and Sorafenib. The models are challenged on data from cell lineage tracing experi-
ments. In those experiments, clones are scored by their cell numbers (clone size) and from the
statistical ensemble of clones, we determine the frequency distribution of clone sizes, the clone
size distribution (CSD). These data serve as the basis to test the validity of the models and to
determine model parameters through fitting.
First, the established model for homeostatic cell fate dynamics in oesophagus (1) is intro-
duced and challenged on clonal data from Sorafenib-treated tissue. For modelling the cell fate
dynamics in high-grade squamous dysplasia (HGD) and invasive tumours, we suggest a simple
adjustment of this model to account for cell fate imbalance and test whether this is consistent
with cell lineage data.
1 Modelling and Fitting procedure
Basic model: From clonal analysis of oesophagus (1) it is known that progenitor cell fate
evolves according to the paradigm of stochastic cell fate (2, 3). In this model, oesophageal
progenitors P divide stochastically with rate λ and either daughter cell may exit cell cycle and
1
commit to differentiation, termed a D-cell, according to the rules
P
λ−→

P + P Prob. r duplication
P +D Prob. 1− 2r asymmetric cell division
D +D Prob. r symmetric differentiation .
(1)
The probabilities of gain and loss of progenitor cells, given by the fate outcomes P → P + P
and P → D + D must be equal to achieve homeostasis. Following division, D-cells may
migrate to the suprabasal layers (stratification, with rate γ), then denoted as D∗-cells.
D
γ−→ D∗ (stratification) . (2)
Finally, cells progress toward terminal differentiation, and eventually lose their nuclei (with rate
σ), after which they are considered lost
D∗ σ−→ ∅ (loss of nucleus) . (3)
This model has been shown to describe clonal dynamics in normal oesophagus (1). Here we
test if these cell fate rules also hold for tissue challenged by the treatment of Sorafenib. For that
purpose, the quantitative predictions for clonal evolution are compared with the experimentally
obtained clone size distributions (CSDs). We employ stochastic simulations, using a Gillespie
algorithm (4), to compute the time evolution of clones. In these simulations, the stochastic
rules 1 - 3 are applied starting with a single progenitor cell, and the statistical distribution of
clone sizes is determined. The model outcome is then compared to the data, and the Bayesian
certainty of the model parameters is computed to assess the goodness of the model, as described
in the following. In section 2.3 we show that cell fate dynamics in HGD can be recovered by
a slight adjustment of this model, by allowing cell fate imbalance between duplication and exit
of cell cycle. In that scenario, however, D-cells only partially differentiate.
The presented model is a paradigmatic example for the neutral competition of progenitor
cells within an equipotent progenitor cell population. Note that other implementations of this
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paradigm, for example one allowing reversible priming of progenitor cells for differentiation
or proliferation, may lead to similar predictions on clonal statistics. Yet, such details of the
dynamics could not be resolved by the available cell lineage data, and thus we focus here on
the simpler question whether the paradigm of a single equipotent progenitor population is sus-
taining the tissue renewal and tumour growth. The model used here is one representative of this
more broadly defined class of cell fate dynamics.
Fitting procedure: For fitting the model to the data, we follow a Bayesian approach, similar
to the one used to infer cell fate rules in normal oesophageal epithelium (1). The certainty of
a set of parameter values θ = (λ, r, γ, σ) 1, in view of the data D, can be quantified by the
Bayesian certainty (also called Bayesian posterior probability)
P (θ|D) = N P (D|θ)P (θ) (4)
where P (D|θ) =: L(θ) is the likelihood of θ, i.e. the probability that the model with parameter
values θ reproduces the data, and the prior P (θ) is the a priori certainty of the model parame-
ters, without taking into account D. The factorN = ∑θ P (D|θ)P (θ) is a normalisation for the
probability. The prior P (θ) is an estimate of the parameter certainty due to information from
other sources, e.g. previous measurements. We choose as a prior the distribution with maximal
entropy, matching the given information. Without further information this is a uniform distri-
bution; if a mean and variance is known, and the variance is much smaller than the mean2, we
choose a normal distribution as prior.
In our case, we have additional information on cell kinetics by measurements of Histone-
GFP (HGFP) dilution (see section 2.1) which restricts the possible range for the cell division
rate. In these measurements the cell division rate is determined with mean λ¯ and standard error
1For the later introduced model of clonal dynamics in dysplasia (section 2.3), parameters differ: θ = (λ, r, µ, δ).
2Strictly speaking, a gamma distribution would be the maximum entropy prior. If the standard deviation is
small compared to the mean, however, this can be approximated by a normal distribution.
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σλ by linear regression. The maximum entropy prior for given mean and standard error is a
normal distribution
P (θ) =
1√
2piσ2λ
exp
[
−(λ− λ¯)
2
2σ2λ
]
. (5)
The model with parameters θ predicts the probabilities pb,s(θ) to observe clones with b basal
and s suprabasal cells. The data is given in the form of the detailed clone size distribution
(detailed CSD) D = {fb,s}b,s, where fb,s is the frequency of measured clone sizes with b basal
and s suprabasal cells. Under the model assumptions, the probability to observe a clone with
(b, s) cells exactly fb,s times follows a multinomial distribution
L(θ) = P (D|θ) = [
∑
b,s fb,s]!∏
b,s fb,s!
×
∏
b,s
pb,s(θ)
fb,s , (6)
as shown in the supplementary note of Ref. (1). When only the total cell number per clone is
available from the data, D = {fn}, Eq. 6 is evaluated with a single index n instead of b, s. Note
that only clones with more than one cell are counted to eliminate the possibility of counting
induced D-cells (cf. discussion in Ref. (1)). With the results of simulation and Eq. 6, the
likelihood of parameters θ is computed and the Bayesian certainty determined with the prior
P (θ) taken from the HGFP measurements. When data from different time points is available,
the full likelihood is obtained by multiplying the individual likelihoods of each time point.
To find the set of best fit parameter values θ∗ = (θ1, θ2, ...), the parameter space is ’scanned’
on a close-meshed grid in intervals ∆θi from minimal values θmini to maximum values θ
max
i ,
and the Bayesian certainty P (θ|D) is determined for each θ (see Ref. (5) for details). For each
set of parameters, n = 150000 clones are simulated and the Bayesian certainty is determined
according to Eq. 6, and the prior, Eq. 5. The benchmarks of the parameter space scan are given
in Table 1. The parameter values θ∗ with the maximum Bayesian certainty, P ∗ := P (θ∗|D), are
chosen as best fit parameter values.
In order to determine error margins for parameters, we compute the root-mean-squared
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deviation of parameters from θ∗ when distributed according to the Bayesian posterior prob-
ability distribution that has been determined as described above. For that purpose, n=10000
parameter value points θα (α = 1, ..., n) are generated randomly, following the Bayesian
posterior probability distribution. The error of each parameter θi is then computed as δθi =√
n−1
∑n
α=1(θ
α
i − θ∗i )2.
Error margins of data points in clone size distributions: Since the abundance of clones of
a given clone size may be very small in the experimental data, it is subject to substantial statis-
tical noise. In order to obtain the range of deviations from the expected clone frequencies, we
simulate by our model the data fluctuations due to small clone sample numbers. In that process,
we run the stochastic simulations n = 1000 times repeatedly, taking the best fit parameters θ∗
and simulate the same total clone number as counted in the lineage tracing experiments. Each
sample simulation j gives a prediction for the clone frequencies f jb,s of finding b basal and s
suprabasal cells, and we take the standard deviation of the set {f jb,s}j as the error margin. These
error margins are shown in the following plots of the CSDs as error bars (detailed CSDs) or blue
shaded areas (total/basal cell CSDs), which mark the expected range of the deviations between
data and model prediction.
We have also checked the mouse-to-mouse variations in the clone counts and found that
they are comparable to the error originating from small sample size error.
2 Data analysis and model fitting results
In this section we analyse the HGFP fluorescence data to obtain estimates for the cell divi-
sion rate, and we fit cell fate models to clonal data from oesophageal epithelium that has been
disturbed by various measures (administration of Sorafenib and DEN). The best fit parameter
values and parameter error margins will be determined according to the procedure described in
5
the last section (rates in units of 1/w = per week, or 1/d = per day).
2.1 Cell division rate from analysis of the HGFP dilution data
In the HGFP dilution experiments, HGFP production is arrested at time point t = 0 when
administration of Doxycycline is stopped. Samples are harvested at 24, 48 and 72 hours af-
terwards. During cell division, HGFP is partitioned equally between daughter cells so that a
cell that has divided i times contains on average a concentration of 2−i times the initial con-
centration of HGFP. The number of cell cycles i a given cell has traversed since a given time
point t0 (the cell generation) can thus be obtained from the HGFP fluorescence intensity f , as
i = log2(f0/f), where f0 is the fluorescence at time t0. Here we will use t0 = 24 hours as the
reference time, as argued below. By measuring the fluorescence levels for an ensemble of basal
cells we determine the frequency distribution of cell generations and the mean cell generation.
Our aim is to determine the average cell division rate of proliferating cells. However, the
ensemble of HGFP-labelled cells may also contain non-dividing cells, which cannot be distin-
guished from progenitor cells. Without further analysis, scoring the fluorescence of all cells
can therefore distort the average, which is meant to be over progenitor cells only. Therefore we
need to correct for non-dividing cells, as will be outlined in the following.
Denoting by ni the mean number of progenitor cells and mi the mean number of non-
dividing cells in generation i, respectively, the time evolution of the cell populations in each
generation reads
∂tn0 = −λn0 ∂tm0 = −γ m0 (7)
∂tni = λ (ni−1 − ni) ∂tmi = λni−1 − γ mi
where λ is the cell division rate, and γ the stratification rate of non-dividing cells. It is assumed
that progenitor cells are not immediately lost, and that cell fate imbalance does not play a
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significant role over the short time periods (3 days) considered in the HGFP dilution assay.
By measuring HGFP fluorescence levels of each cell, we can only determine the total fraction
of cells in a given generation i, zi = ni + mi, not of individual cell types. The mean cell
generation of all cells, i¯ := Z−1
∑
i i zi, is related to the mean cell generation of progenitor cells
i¯P := N
−1∑
i i ni, and of non-dividing cells i¯D := M
−1∑
i imi (Z :=
∑
i zi, N :=
∑
i ni,
M :=
∑
imi) through
i¯ =
1
Z
∑
i
i (ni +mi) =
N
Z
1
N
∑
i
i ni +
M
Z
1
M
∑
i
imi (8)
= ρ i¯P + (1− ρ) i¯D ,
where ρ := N/Z is the fraction of progenitor cells. The means i¯P,D have the time evolution
∂ti¯P =
1
N
∑
i
i ∂tni =
λ
N
( ∞∑
i=1
i ni−1 −
∞∑
i=0
i ni
)
(9)
∂ti¯D =
1
M
∑
i
i ∂tm =
1
M
(
λ
∞∑
i=1
i ni−1 − γ
∞∑
i=0
imi
)
.
With the substitution i→ i+ 1 we have
∑
i=1
i ni−1 =
∑
i=0
(i+ 1)ni = N(1 + i¯P ) , (10)
so that
∂ti¯P = λ (11)
∂ti¯D =
λN
M
(1 + i¯P )− γ i¯D .
With i¯P,D(t = t0) = 0, and since in the stationary state N/M = γ/λ, we get the solution of
these ordinary differential equations
i¯P (t) = λ t (12)
i¯D(t) = λ t− λ/γ + 1 + e−γt(λ/γ − 1) .
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Differentiating for t and substitution of this result in Eq. 8 gives
∂ti¯ = λ− (1− ρ) γ e−γt
(
λ
γ
− 1
)
≈ λ
(
for t 1
γ
)
(13)
Hence, the slope of the time course of the mean cell generation of all cells is a good approxi-
mation for the cell division rate λ of progenitor cells for large times t γ, or if λ ≈ γ.
Since the result depends only on the time derivative of the mean cell generation – which does
not depend on f0 – we can define the reference fluorescence level f0 as the fluorescence at 24
hours, thus counting cell generations from day 1 after Dox withdrawal. Thereby uncertainties
in the time scale of Dox withdrawal are avoided.
The mean cell generation, defined as i¯(t) = 〈log2(f0/f(t))〉, is shown as a function of time
in Supplementary Fig. 5a for Sorafenib-only treated tissue and in Fig. 6i for tissue treated
with DEN and Sorafenib, both inside and outside of the dysplastic region. Since for each
animal, measurements can only be obtained at a single time point, but the definition of the
cell generation involves two time points, no measurements of the cell generations in individual
animals is available. Despite this, the mean value of i can be obtained from averaging the
logarithmic fluorescence at individual time points over different animals, as i¯ = 〈log2(f0)〉 −
〈log2(f)〉. However, the exact s.e.m. of i cannot be obtained from the data alone, since we have
no information about the correlation of f0 and f(t) for individual animals. Instead we chose to
give the s.e.m of 〈log2(f)〉 at individual time points in Supplementary Fig. 5a and Fig. 6i, which
give an upper estimate of the s.e.m of i, but implicitly include variations of initial fluorescence
levels. The true s.e.m. of the cell generations can be indirectly inferred from the residuals of
the model fit (see below and Supplementary Fig. 6d).
We see in Supplementary Fig. 5a and Fig. 6i that the data points follow a straight line with
constant slope for each case. This suggests, according to Eq. 13, that we are in the regime
where the slope of i(t) approximates the cell division rate well. With this approximation, a
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linear regression yields in all three cases a cell division rate very close to once per day. The
results of the fitting and error margins (standard deviation of the fit’s χ2-distribution) are shown
in Supplementary Fig. 6d, as well as the corresponding residuals which estimate the s.e.m.
of the individual data points. In the following we will use this information for constructing a
Bayesian prior for fitting the clonal data. As a maximum entropy prior with given mean and
variance, we use a Gaussian function P (λ) = (2piσ2λ)
−1/2 exp(−(λ− λ¯)2/(2σλ)) where λ¯ is the
best fit value of the regression and σλ its standard error (see Supplementary Fig. 6d).
The distributions of cell generation times are shown in Supplementary Figs. 5b,6b,c for
Sorafenib-only treatment, DEN+Sorafenib treatment inside HGD, and DEN+Sorafenib treat-
ment in tissue adjacent to HGD, respectively. Remarkably, for Sorafenib-only treatment, the
generation distributions keep their shape and are merely shifted by one cell cycle between sub-
sequent days which indicates that cell cycle times are highly uniform with a length of 24 hours.
This would be expected if cell divisions were limited by the circadian clock and is consistent
with the strong diurnal regulation of proliferation in the oesophagus (6).
2.2 Clonal analysis in Sorafenib-treated tissue
In the first experiment, animals were pre-treated with Sorafenib for 28 days before clones were
induced, and tissue was harvested 12 days later. In order to infer cell fate dynamics in tissue
treated with Sorafenib, we fit the parameters of the model according to the procedure outlined
in section 1. The benchmarks of the fitting procedure (scanning the parameter space for deter-
mining the Bayesian certainty distribution) are given in Table 1. The resulting best fit parameter
values and root-mean-square errors are given by
λ = 7.0± 0.2/w r = 0.02± 0.01 γ = 6.8± 0.9/w σ = 2.6± 0.2/w , (14)
The error margins denote root-mean-square deviations from the best fit values as described in
section 1.
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(a) (b)
parameter θmini θ
max
i ∆θi
λ [w−1] 6.4 7.6 0.2
r 0 0.075 0.005
γ [w−1] 4.0 10.4 0.2
σ [w−1] 1.6 4.0 0.2
parameter θmini θ
max
i ∆θi
λ [w−1] 5.6 8.0 0.4
r 0 0.075 0.005
γ [w−1] 4.0 10.4 0.2
σ [w−1] 1.6 4.0 0.2
(c)
parameter θmini θ
max
i ∆θi
λ [w−1] 6.90 7.10 0.05
r 0.10 0.085 0.005
µ [w−1] 0.3 2.2 0.1
δ 0 1.0 0.1
Table 1: Benchmarks of scanning the parameter space for obtaining Bayesian certainties for
(a) tissue from animals treated with Sorafenib only, (b) tissue from animals treated with DEN
and Sorafenib, adjacent to dysplasia, (c) dysplastic tissue from animals treated with DEN and
Sorafenib. The respective models were simulated and Bayesian certainties determined, for a
close-meshed set of parameters: the parameter space was scanned in a grid with scanning in-
terval between parameter values, ∆θi, minimum, θmini , and maximum parameter values, θ
max
i ,
as given in the table. For DEN+Sorafenib treatment in dysplasia, clones with size larger than
40 are neglected for determining Bayesian certainties. These outliers are consistent with the
expected range of clone fusions, as argued in the text.
10
The detailed CSD, showing distinct basal and suprabasal cell numbers, which was used for
the fitting, is displayed for Sorafenib-treated mice in Supplementary Fig. 5c. The corresponding
total CSD, comprising basal and suprabasal cell numbers in a clone, are shown in Fig. 5f. The
model fits show excellent agreement with the experimental data.
To verify the model and the best fit parameters we tested its prediction on clonal data of the
same experiment but clones harvested 21 days after clonal induction. The results for the joint
CSD are shown in Supplementary Fig. 5j, for the basal CSD in Supplementary Fig. 5h, and
for the total CSD in Supplementary Fig. 5i, giving a good agreement between model and data,
thereby confirming the results of our fit.
Note that our model does not account for the apparent low variation of cell cycle times, as
inferred from the HGFP data analysis in the previous section. To test whether this changes the
model predictions for clone size distributions, we simulated a version of the model in which the
timing between consecutive cell divisions is fixed. In this simulation, cells divide at discrete
time points in intervals 1/λ. To assure that the proportion of progenitor cells ρ is the same as
for stochastic divisions, D-cells stratify between two cell divisions with probability pγ = ρ =
γ/(λ+ γ). This can be seen by checking the stationary state condition for the mean number of
D-cells:
mt+1 = (mt + nt)− pγ (mt + nt) = mt ⇒ pγ = nt
mt + nt
=
γ
λ+ γ
. (15)
where the latter identity is derived from the stationary state condition of the stochastic model
λnt = γ mt. For the best-fit parameters for Sorafenib treatment, 14, the predicted basal CSD
(counting basal cells per clone only) is shown and compared with the results from the stochastic
model in Supplementary Fig. 5d. No significant difference between the two implementations
can be seen within the error margins of the data.
In a control experiment, mice were given the vehicle without Sorafenib, and clones were
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harvested after 12 days. If the vehicle does not affect cell fate dynamics itself, the model with
parameter values from normal oesophageal epithelium (1) should reproduce the clonal data of
this control experiment. Assuming cell cycle times of normal tissue, only three cell cycles have
on average been completed after 12 days. While our stochastic model does not capture the
synchronicity in differentiation of suprabasal cells at short times (after a few cell cycles), the
stochastic fate of basal cells is well reproduced by the model with normal-tissue parameters, if
clones with a single basal cell are excluded3. This is shown in Supplementary Fig. 5e, where the
basal CSD from the experiment and model predictions for parameters of normal oesophageal
epithelium, taken from Ref. (1), are compared.
Comparing the best fit parameters for tissue from Sorafenib-treated mice with normal tissue
(see Supplementary Table 5), we see that the ratio of symmetric cell divisions r is significantly
decreased, so that almost all cell divisions (1− 2 r = 96%) result in asymmetric fate outcome.
Furthermore, both the stratification rate and the cell division rate are significantly increased.
2.3 Clonal analysis in tissue treated with Sorafenib and DEN
For studying cell fate dynamics in HGD, mice were treated with DEN for 8 weeks, and then
Sorafenib was administered for 4 weeks before clones were induced. 13 days and 22 days after
induction the mice were culled and clones counted.
Clonal analysis in tissue surrounding HGD: We scored clones collected from tissue sur-
rounding HGD, taken 13 days after induction and fitted the model parameters to the detailed
CSD, according to the program of section 1. The benchmarks of scanning the parameter space
to find best-fit values and error margins are shown in Table 1. The best fit parameter values and
3Compare detailed discussion in Ref. (5), where it is argued that the stochastic model describes the dynamics
of basal cells well even after short times, if single basal cells are neglected.
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root-mean-square errors of this fit are:
λ = 6.8± 0.4/w r = 0.05± 0.01 γ = 7.0± 1.3/w σ = 2.6± 0.3/w (16)
The corresponding detailed CSD is shown, together with the data, in Supplementary Fig. 6g,
which shows an excellent agreement. As expected, we see that these best fit parameter val-
ues are not very different from the case of Sorafenib-only treatment; there is an overlap of the
acceptable parameter regimes, except for a slightly significant difference in the symmetric divi-
sion ratio r. Thus, DEN treatment does not markedly alter cell fate dynamics in non-dysplastic
tissue.
Clonal analysis in HGD: Inside HGDs we expect cell fate dynamics to be non-homeostatic.
In this case, we sought for the minimal adjustment of the homeostatic model that could capture
the clonal dynamics, by assuming normal cell fate dynamics of the form given by rules 1, but
with a tilt towards proliferation:
P
λ−→

P + P Prob. r(1 + δ) duplication
P +D Prob. 1− 2r asymmetric cell division
D +D Prob. r(1− δ) symmetric cell cycle exit ,
(17)
where δ quantifies the tilt in cell fate 4 (δ = 0 corresponds to homeostasis δ = 1 implies absence
of symmetric cell cycle exit). Furthermore, we accommodate the observation that proliferating
cells are also found in the suprabasal layers of the dysplastic epithelium and that non-dividing
cells show signs of early differentiation, but terminal differentiation is suppressed. Therefore,
we do not explicitly distinguish between basal and suprabasal cells in the model, and we only
consider one type of non-dividing cellD, irrespective of the distance to the basement membrane
and differentiation stage. Non-dividing D-cells are shed with loss rate µ:
D
µ−→ ∅ . (18)
4Note that in Supplementary Table 5, where best fit parameter values are given, the value of the absolute cell
fate bias ∆ := r δ is given.
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Note that loss ofD-cells may thus occur before terminal differentiation. In order to compare this
with the loss of cells in normal stratified epithelium, we need to find a corresponding quantity
in latter case. We note that µ = 1/τ , where τ is the mean “life time” of a D-cell, from birth to
loss. For scenarios in which basal and suprabasal cells are distinguished, the mean life time is
τ = 1/γ + 1/σ. Thus, in this case, the absolute loss rate is µ = (1/γ + 1/σ)−1 and the values
for the different scenarios can be compared, as given in Supplementary Table 5.
To fit the model, we compared the distributions of total clone sizes (total CSD) between
model and experiment, according to Eq. 4, at both 13 and 22 days post-induction (multiplying
likelihoods at both time points). The benchmarks of scanning the parameter space to find best-
fit values and error margins are shown in Table 1. The resulting best fit parameter values and
root-mean-square errors are given by:
λ = 7.0± 0.1/w r = 0.05± 0.02 µ = 0.9± 0.7/w δ = 0.4± 0.2 . (19)
With these parameter values, the corresponding plot of the clone size distribution (model
prediction and data) is shown in Fig. 7c for clonal data 13 days after induction and in Supple-
mentary Fig. 6e for data collected 22 days after induction. Due to low numbers for fixed clone
size, the clone counts at 22d after induction were binned in intervals of width 5 {[0, 5], [6, 10], ...}.
The simulation results with the best fit parameters match well both the clonal data at 13 days
and at 22 days post-induction, apart from a few outliers with very large clone size. However,
it cannot be excluded that clones merge, forming polyclonal clusters that cannot be distin-
guished, due to identical colours. We therefore repeated the experiment with mice carrying a
confetti allele, which allows randomly labelling with four different colours, thereby reducing
the probability that clones with the same colour merge. Fitting this clonal data gives the best fit
parameters
λ = 6.95± 0.05/w r = 0.03± 0.015 µ = 2.0± 0.3/w δ = 0.7± 0.3 . (20)
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where the error ranges denote the standard deviation of the Bayesian posterior. In this fit a single
outlier with clone size 59 cells was excluded from the data at 21 days after induction. Fig. 7g
and Supplementary Fig. 6h shows the corresponding clone size distributions 10 and 21 days
after clonal induction, showing good agreement between model and data. The parameters from
fitting both the single colour and the confetti assay are similar with overlapping error ranges
in the parameters λ, r, and δ. However, the loss rate µ is significantly higher for the confetti
mouse data, which may be explained by the higher sensitivity for differentiated cells in the
single colour assay.
Furthermore we check theoretically whether the outliers in the single-colour data are within
the range of expected clone fusion events. Fig. 6b,c shows almost circular whole-mounts of
lesions, in which proliferating cells are at the rim of HGD lesions while non-dividing cells flow
radially towards the centre, relative to the growing rim. Thus we estimate that the width of
a clone in angular direction of the lesion is entirely determined by the number of progenitor
cells in that clone. Since there are no clones spanning the lesions across the centre, and no
arc-shaped clones have been detected, we conclude that clones only merge in angular direction.
13 days after induction, we found on average 5.32 clones per HGD, with an average lesion
circumference of l = 2.23 mm. Since the mean cell diameter is 0.01 mm, this corresponds
to a clone frequency of φ = 0.024 clones per peripheral cell. For the analysis we define the
position of a clone as the point that is furthest clockwise at the rim. A given clone A does not
touch its next neighbour clone B in anti-clockwise direction, if both clones are further apart
from each other than the width s of clone A (in angular direction). Then the probability of two
neighbouring clones being separated is
P¯t =
∞∑
s=1
(1− φ)s P (s, s¯) (21)
where P (s, s¯) is the probability distribution of clone widths (mean clone width s¯), which, ac-
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cording to our assumption above, corresponds to the distribution of progenitor cell numbers in
a clone. According to our model, the progenitor cells perform a supercritical branching process
which follows the distribution P (s, s¯) = e−s/s¯ × (e1/s¯ − 1) (7). With a cell division rate of
λ = 7.0/w and a loss rate of µ = 0.9/w (best fit values) we have an equilibrium fraction of
proliferative cells of ρ = µ/(µ+ λ) = 11.4% in a clone. 13 days after induction, the mean size
of clones is n13 = 9.57, yielding s¯ = ρ n13 = 1.09. From Eq. 21 we then get P¯t = 0.961, corre-
sponding to an expected fraction of merged clones of Pt = 1− P¯t = 3.9%. We see 5 clones out
of 100 counted (5%) to lie outside the error margin of the model prediction for the data taken
13 days after induction and 4 out of 68 (5.9%) after 22 days. This is is well consistent with the
expected fraction of clone fusions for Poisson statistics with standard deviation σ =
√
5 and
σ = 2 counts for 13 and 22 days respectively. Thus, the outliers in the data are not significantly
different from what would be expected as frequency of random clone fusion events.
Remarkably, despite the expected high genetic heterogeneity due to mutagen treatment, the
model can well reproduce the data with a single type of progenitor cells. The majority of cell
divisions is yet asymmetric (1 − 2 r = 90%), and the tilt in cell fate is small, in terms of an
excess in symmetric duplications of 2 r δ = 4%. A comparison of the cell fate parameters
between different scenarios (normal, vehicle-treated, Sorafenib-treated, and DEN+Sorafenib-
treated tissue) is shown in Supplementary Table 5.
2.4 Kras-induction and Sorafenib administration after treatment with
DEN
In the final experiment, an oncogenic Kras mutant was induced together with YFP after 8 weeks
of DEN administration. When clones were induced, also Sorafenib treatment started. Invasive
tumours emerged, and at 42 and 56 days after induction clones were scored in those tumours.
The number of clones that could be recorded is scarce and the computational effort required
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for effective model fitting is too high to perform because of the large clone sizes. Yet we can
check whether the cell fate paradigm of pre-malignant lesions in oesophagus prevails. To assess
this, we first checked whether some clones follow the same dynamics as clones in pre-malignant
DEN-induced HGD, despite of Kras activation. For that purpose we first restrict our analysis
to “small” clones by defining a cut-off size up to which clones are considered. The cut-off is
chosen as the average maximal clone size one would expect under the clonal dynamics observed
in HGDs, and can be determined by extreme value theory (8). Assuming an exponential CSD,
the expected maximum clone size is zmax = (ln(N) + γe) × z¯, where N is the number of
clones, γe the Euler-Mascheroni constant, and z¯ the mean clone size. This results in an expected
maximum clone size of 147 at 42 days after induction and a maximum expected maximum size
of 147 at 56 days after induction. We will thus use these numbers as cut-off for our analysis.
Considering only clones below this threshold (65 out of 98 at 42 days, and 25 out of 40 at
56 days after induction), the clonal data is matched well by the prediction from model 17 with
the parameters inferred for HGD clonal dynamics, without Kras, as shown in Fig. 8g at 42 days
after induction and in Supplementary Fig. 7c at 56 days after induction. Hence, for the majority
of clones, Kras induction does not have a significant impact on clonal dynamics.
However, there is still a large fraction of clones which are significantly larger than would
be expected from dynamics in pre-malignant HGD. We want to test if these clones can yet be
described by the tilted stochastic fate paradigm, rules 17, albeit with a higher cell fate bias. Al-
though we cannot fit the data, we can use an analytical approximation for the model prediction:
after long times the clone size distribution approaches a distribution as expected from a super-
critical branching process, which yields an exponential distribution P (z) = 1/z¯ exp(−z/z¯),
where z¯ is the mean clone size (7). Thus, the model rules 17 would predict the data points to
collapse on the exponential curve when clone sizes are rescaled by the mean clone size. If the in-
vasive super-large clones are excluded, the mean clone size z¯ is 499 cells per clone after 42 days
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and 560 cells per clone after 56 days. The resulting rescaled clone size distributions are shown
in Fig. 8h and Supplementary Fig. 7d respectively (binned in intervals of 100, starting with
size 150 for 42 days and with size 200 for 56 days after induction). Note that due to the lower
cut-off c at z = 150, 200, the theoretical prediction is re-normalised by the normalisation factor
N = (∑∞i=dc/100e exp(−100 i/z¯))−1, so that the theoretical prediction is P (z) = N exp(−X),
where X = z/z¯ − 50 (the function is shifted by half a binning interval to be evaluated in the
middle of the interval). This shows an excellent agreement between theoretical prediction and
the rescaled data. Thus we can conclude that the vast majority of clones in the invasive tumours
is consistent with the tilted stochastic cell fate paradigm.
From this data are excluded the ’mega-clones’ with several thousands of cells which do not
match the predicted distributions. Although it could be possible that an even higher cell fate
bias can accommodate for their size, the number of those clones is too small to test this.
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